Literature DB >> 26578817

Biophysical characterization of laforin-carbohydrate interaction.

David M Dias1, Joana Furtado2, Emeric Wasielewski3, Rui Cruz2, Bernard Costello4, Lindsay Cole4, Tiago Q Faria5, Philipp Baaske6, Rui M M Brito7, Alessio Ciulli8, Isaura Simões9, Sandra Macedo-Ribeiro10, Carlos Faro9, Carlos F G C Geraldes11, Pedro Castanheira12.   

Abstract

Laforin is a human dual-specificity phosphatase (DSP) involved in glycogen metabolism regulation containing a carbohydrate-binding module (CBM). Mutations in the gene coding for laforin are responsible for the development of Lafora disease, a progressive fatal myoclonus epilepsy with early onset, characterized by the intracellular deposition of abnormally branched, hyperphosphorylated insoluble glycogen-like polymers, called Lafora bodies. Despite the known importance of the CBM domain of laforin in the regulation of glycogen metabolism, the molecular mechanism of laforin-glycogen interaction is still poorly understood. Recently, the structure of laforin with bound maltohexaose was determined and despite the importance of such breakthrough, some molecular interaction details remained missing. We herein report a thorough biophysical characterization of laforin-carbohydrate interaction using soluble glycans. We demonstrated an increased preference of laforin for the interaction with glycans with higher order of polymerization and confirmed the importance of tryptophan residues for glycan interaction. Moreover, and in line with what has been described for other CBMs and lectins, our results confirmed that laforin-glycan interactions occur with a favourable enthalpic contribution counter-balanced by an unfavourable entropic contribution. The analysis of laforin-glycan interaction through the glycan side by saturation transfer difference (STD)-NMR has shown that the CBM-binding site can accommodate between 5 and 6 sugar units, which is in line with the recently obtained crystal structure of laforin. Overall, the work in the present study complements the structural characterization of laforin and sheds light on the molecular mechanism of laforin-glycan interaction, which is a pivotal requisite to understand the physiological and pathological roles of laforin.
© 2016 Authors; published by Portland Press Limited.

Entities:  

Keywords:  Lafora disease; carbohydrate-binding module; glycogen; laforin; protein–carbohydrate interaction

Mesh:

Substances:

Year:  2015        PMID: 26578817     DOI: 10.1042/BJ20141555

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  5 in total

Review 1.  Structural biology of glucan phosphatases from humans to plants.

Authors:  Matthew S Gentry; M Kathryn Brewer; Craig W Vander Kooi
Journal:  Curr Opin Struct Biol       Date:  2016-08-04       Impact factor: 6.809

2.  Escherichia coli Topoisomerase IV E Subunit and an Inhibitor Binding Mode Revealed by NMR Spectroscopy.

Authors:  Yan Li; Ying Lei Wong; Fui Mee Ng; Boping Liu; Yun Xuan Wong; Zhi Ying Poh; Shuang Liu; Siew Wen Then; Michelle Yueqi Lee; Hui Qi Ng; Qiwei Huang; Alvin W Hung; Joseph Cherian; Jeffrey Hill; Thomas H Keller; CongBao Kang
Journal:  J Biol Chem       Date:  2016-06-30       Impact factor: 5.157

Review 3.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

4.  Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.

Authors:  Felix Nitschke; Mitchell A Sullivan; Peixiang Wang; Xiaochu Zhao; Erin E Chown; Ami M Perri; Lori Israelian; Lucia Juana-López; Paola Bovolenta; Santiago Rodríguez de Córdoba; Martin Steup; Berge A Minassian
Journal:  EMBO Mol Med       Date:  2017-07       Impact factor: 12.137

Review 5.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.